argenx SE (NASDAQ:ARGX) Shares Bought by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC boosted its stake in shares of argenx SE (NASDAQ:ARGX) by 23.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 121 shares of the company’s stock after buying an additional 23 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in argenx were worth $74,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Victory Capital Management Inc. grew its position in shares of argenx by 69.8% in the third quarter. Victory Capital Management Inc. now owns 1,562 shares of the company’s stock valued at $847,000 after purchasing an additional 642 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of argenx in the third quarter valued at approximately $453,000. OneDigital Investment Advisors LLC grew its position in shares of argenx by 13.2% in the third quarter. OneDigital Investment Advisors LLC now owns 1,194 shares of the company’s stock valued at $647,000 after purchasing an additional 139 shares during the last quarter. Natixis Advisors LLC grew its position in shares of argenx by 13.0% in the third quarter. Natixis Advisors LLC now owns 12,014 shares of the company’s stock valued at $6,513,000 after purchasing an additional 1,379 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its position in shares of argenx by 1.5% in the third quarter. Thrivent Financial for Lutherans now owns 37,352 shares of the company’s stock valued at $20,248,000 after purchasing an additional 564 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on ARGX shares. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a “sell” rating to a “hold” rating in a research report on Wednesday, March 12th. Sanford C. Bernstein upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research report on Monday. Citigroup reiterated an “outperform” rating on shares of argenx in a research report on Friday, February 28th. William Blair reissued an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Finally, Piper Sandler upped their price objective on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, argenx presently has an average rating of “Moderate Buy” and an average price target of $687.00.

argenx Stock Down 0.5 %

NASDAQ:ARGX opened at $611.18 on Wednesday. argenx SE has a fifty-two week low of $349.86 and a fifty-two week high of $678.21. The firm’s 50 day moving average is $636.83 and its two-hundred day moving average is $598.22. The company has a market cap of $37.14 billion, a P/E ratio of -694.52 and a beta of 0.59.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. Research analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.